Overview

Clinical Study in the Treatment of Patients With Moderate Course of COVID-19

Status:
Recruiting
Trial end date:
2021-10-05
Target enrollment:
Participant gender:
Summary
Study of safety, efficacy and pharmacokinetics, dose selection
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Microgen
Microgen Scientific Industrial Company for Immunobiological Medicines
Treatments:
Immunoglobulins
Immunoglobulins, Intravenous